Abstract 180P
Background
Along with the prolonged survival of cancer patients in recent years comes another dilemma, multiple primary cancers (MPC), which rob cancer patients of their privilege to optimal treatments. Nonetheless, understanding the hereditary and postnatal predisposition of MPC is still in its infancy.
Methods
We included 47,550 cancer patients in UK Biobank. Hazardous and protective HLA alleles concerning MPC were recognized leveraging stepwise logistic regression, which was further validated by log-rank test and Cox proportional hazard model. Logistic regression was used to investigate the organ-specific association between HLA and MPC. Cox proportional hazard model was used to explore potential interventions.
Results
Two protective (DPA1*02:02 and DRB1*04:03) and four hazardous (A*26:01, A*24:03, DPB1*20:01 and DQB1*06:01) HLA alleles are significantly associated with MPC risk for male, whereas one protective (DRB5*01:01) and four hazardous (A*03:02, DRB1*08:03, DQB1*05:04, and DPB1*11:01) for female. Compared with patients without MPC-related HLA alleles, both male and female patients carrying protective HLA alleles have lower risk of MPC (HR, 0.67 [95% CI, 0.53-0.83] and HR, 0.84 [95% CI, 0.73-0.97], respectively), while those carrying hazardous HLA alleles have higher risk of MPC (HR, 1.31 [95% CI, 1.09-1.57] and HR, 1.55 [95% CI, 1.25-1.93], respectively). HLA alleles are associated with organ-specific MPC occurrence. Lower animal fat intake subsided (HR, 0.46 [95% CI, 0.26-0.82]) while unqualified vegetable fat intake increased MPC risk (HR, 2.23 [95% CI, 1.22-4.07]) for male cancer patients carrying hazardous HLA alleles. Lower free sugar intake subsided the risk of MPC for female patients carrying hazardous HLA alleles (HR, 0.34 [95% CI, 0.15-0.74]).
Conclusions
HLA alleles might help to understand the predisposition and organ-specific incidence of MPC. Intervention on diet could counteract the risk.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Zhongyi Dong.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
217P - Clinical and molecular features of PTCH1 mutant in solid tumors
Presenter: Xuezheng Li
Session: Poster session 01
218P - Peripheral T cell activation phenotype is associated with clinical outcomes and immune-related adverse events of ipilimumab-nivolumab in advanced hepatocellular carcinoma
Presenter: WON SUK LEE
Session: Poster session 01
219P - Multicentric evaluation of amplicon-based next-generation sequencing solution for local comprehensive molecular tumor profiling
Presenter: Eloisa Jantus Lewintre
Session: Poster session 01
220P - Biomarker of blood age and inflammation in older cancer patients might predict outcome
Presenter: Marcus Vetter
Session: Poster session 01
221P - Peripheral T cell activation phenotype predicts clinical outcomes of atezolizumab-bevacizumab therapy in unresectable hepatocellular carcinoma
Presenter: Chan Kim
Session: Poster session 01
222P - Therapeutic opportunities for porcupine inhibition in gastrointestinal cancer
Presenter: Natalie Cook
Session: Poster session 01
223P - Artificial intelligence-based pathomics biomarker predict primary resistance to first-line treatment in metastatic colorectal cancers
Presenter: Gianluca Mauri
Session: Poster session 01
224P - Germline HLA-I/II is not associated with clinical outcome but the absence of HLA-A01 or the presence of HLA-B27 supertypes were correlated with improved clinical outcome among patients with NSCLC treated with pembrolizumab in combination with chemotherapy
Presenter: Afaf Abed
Session: Poster session 01
225P - Utility of next-generation sequencing (NGS) in patients with advanced cancer in a low-middle income country
Presenter: Milton Lombana Quinonez
Session: Poster session 01
226P - LongiBloodImmunoM: A multi-step analysis pipeline for longitudinal blood-based immunomonitoring for immunotherapy clinical trial
Presenter: Jiangfeng Ye
Session: Poster session 01